Cost-Utility Analysis of Erlotib Versus Standard Chemotherapy in First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in Vietnam
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1614
https://www.valueinhealthjournal.com/article/S1098-3015(16)01682-X/fulltext
Title :
Cost-Utility Analysis of Erlotib Versus Standard Chemotherapy in First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in Vietnam
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01682-X&doi=10.1016/j.jval.2016.03.1614
First page :
A154
Section Title :
Cancer - Cost Studies
Open access? :
No
Section Order :
336